| P2093 | author name string | J F Westphal | |
| P2860 | cites work | Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues | Q24633406 |
| | The fate of naringin in humans: A key to grapefruit juice-drug interactions? | Q28291236 |
| | Potentially fatal interaction between erythromycin and disopyramide | Q28339582 |
| | A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. | Q52306429 |
| | Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. | Q52534774 |
| | Concomitant digoxin toxicity and warfarin interaction in a patient receiving clarithromycin. | Q53343412 |
| | Potential interaction between clarithromycin and warfarin. | Q53357847 |
| | Clinical ergotism with lingual ischemia induced by clarithromycin-ergotamine interaction. | Q53726625 |
| | Reversal of drug resistance by erythromycin: erythromycin increases the accumulation of actinomycin D and doxorubicin in multidrug-resistant cells. | Q53827442 |
| | Drug interactions and hepatitis produced by some macrolide antibiotics | Q57314144 |
| | Decreased intestinal CYP3A in celiac disease: Reversal after successful gluten-free diet: A potential source of interindividual variability in first-pass drug metabolism* | Q58812433 |
| | Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation* | Q60787070 |
| | From the Food and Drug Administration | Q67493197 |
| | Oxidation of quinidine by human liver cytochrome P-450 | Q69598283 |
| | Effect of erythromycin on theophylline kinetics | Q70197412 |
| | QT interval prolongation and torsades de pointes due to erythromycin lactobionate | Q71003393 |
| | Cisapride and fatal arrhythmia | Q71133416 |
| | Increased hypoprothrombinemic effect of warfarin possibly induced by azithromycin | Q71579159 |
| | Identification of human liver cytochrome P450s involved in the microsomal metabolism of the antihistaminic drug loratadine | Q71883165 |
| | Possible interaction between azithromycin and cyclosporin: a case report | Q71898765 |
| | Effects of clarithromycin and its metabolites on the mixed function oxidase system in hepatic microsomes of rats | Q72217214 |
| | Steady-state pharmacokinetics of theophylline in COPD patients treated with dirithromycin | Q72572985 |
| | Inhibition of terfenadine metabolism. Pharmacokinetic and pharmacodynamic consequences | Q72793332 |
| | Life-threatening interaction between clarithromycin and disopyramide | Q73048067 |
| | Interaction between tacrolimus and erythromycin | Q73065823 |
| | Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin | Q73503614 |
| | Reduced serum theophylline concentrations after discontinuation of azithromycin: evidence for an unusual interaction | Q73571447 |
| | Possible increased anticoagulation effect of warfarin induced by azithromycin | Q74296411 |
| | Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations | Q77206225 |
| | Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences | Q77360269 |
| | The Influence of Dirithromycin on the Pharmacokinetics of Cyclosporine in Healthy Subjects and in Renal Transplant Patients | Q77649359 |
| | P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies | Q78175427 |
| | Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations | Q33173569 |
| | Long QT Syndrome During High-Dose Cisapride | Q33173733 |
| | Intravenous azithromycin. | Q33543121 |
| | Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein | Q34040187 |
| | Characterization of human liver cytochromes P-450 involved in theophylline metabolism | Q34538533 |
| | The effect of erythromycin on the disposition kinetics of warfarin | Q34712426 |
| | Theophylline N-demethylations as probes for P4501A1 and P4501A2. | Q34724083 |
| | Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy | Q34729824 |
| | Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). | Q34756683 |
| | Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes | Q35608569 |
| | Pharmacokinetic drug interactions of macrolides | Q35759081 |
| | Drug metabolism by cytochromes P450 in the liver and small bowel. | Q35787791 |
| | Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine | Q36053651 |
| | The mechanism of cyclosporine toxicity induced by clarithromycin | Q36093902 |
| | Pharmacokinetic drug interactions with cyclosporin (Part I). | Q37956836 |
| | Cisapride: a gastrointestinal prokinetic drug | Q38570021 |
| | Decreased antipyrine clearance following endotoxin administration: in vivo evidence of the role of nitric oxide. | Q39472190 |
| | Steady-state pharmacokinetics and electrocardiographic pharmacodynamics of clarithromycin and loratadine after individual or concomitant administration | Q39558497 |
| | Cytochrome P-450 complex formation by dirithromycin and other macrolides in rat and human livers | Q39864969 |
| | Macrolide antibacterials. Drug interactions of clinical significance | Q40423079 |
| | Recent Advances: the Cytochrome P450 Enzymes | Q40475823 |
| | Possible inhibition of hepatic metabolism of quinidine by erythromycin | Q40575062 |
| | A review of clinical trials comparing HMG-CoA reductase inhibitors | Q40630809 |
| | Hepatic side-effects of antibiotics | Q40677434 |
| | Antipyrine clearance in pneumonia | Q40817512 |
| | The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin | Q40851439 |
| | Clinical pharmacokinetics of newer antibacterial agents in liver disease | Q40884111 |
| | Macrolides versus azalides: a drug interaction update | Q40938716 |
| | Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein | Q41018603 |
| | Biotransformation of caffeine and theophylline in mammalian cell lines genetically engineered for expression of single cytochrome P450 isoforms. | Q41142887 |
| | Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology. | Q41143946 |
| | Theophylline metabolism in human liver microsomes: inhibition studies. | Q41220959 |
| | Human P450 metabolism of warfarin | Q41334623 |
| | Drug interactions of macrolides: emphasis on dirithromycin | Q41380268 |
| | Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. | Q41462331 |
| | Digoxin-cyclosporin A interaction: modulation of the multidrug transporter P-glycoprotein in the kidney | Q41531879 |
| | Human P-glycoprotein transports cyclosporin A and FK506. | Q41565344 |
| | Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). | Q41596609 |
| | Inhibition by erythromycin of the conversion of carbamazepine to its active 10,11-epoxide metabolite | Q41772429 |
| | Age as a determinant of sensitivity to warfarin | Q41946702 |
| | Polymorphisms in oxidative drug metabolism: relationship to food preference | Q42284944 |
| | Torsade de pointes induced by cisapride/clarithromycin interaction | Q42536187 |
| | Erythromycin-induced clozapine toxic reaction | Q42556498 |
| | Seizure following addition of erythromycin to clozapine treatment | Q42563091 |
| | The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. | Q42687064 |
| | Cyclosporin metabolism by human gastrointestinal mucosal microsomes | Q43224335 |
| | Erythromycin enhances the absorption of cyclosporin | Q43229096 |
| | Inhibition of theophylline metabolism by interferon | Q43898227 |
| | Effect of erythromycin in patients receiving long-term warfarin therapy. | Q46148539 |
| | Bioavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction | Q46791680 |
| | The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. | Q50867766 |
| | Interaction between midazolam and clarithromycin: comparison with azithromycin. | Q51563397 |
| | A potentially hazardous interaction between erythromycin and midazolam. | Q51670697 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | clarithromycin | Q118551 |
| | azithromycin | Q165399 |
| P304 | page(s) | 285-295 | |
| P577 | publication date | 2000-10-01 | |
| P1433 | published in | British Journal of Clinical Pharmacology | Q176044 |
| P1476 | title | Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin | |
| P478 | volume | 50 | |